Houman Ashrafian

Houman joined SV in 2016 as a Venture Partner, was promoted to Partner in 2017 and became a Managing Partner in 2018. He has founded and serves on the board of six SV companies; Alchemab, Catamaran Bio, Enara Bio, Mestag, Sitryx and TrexBio. Houman serves on the Dementia Discovery Fund (DDF) Investment Committee and on the Therini Board. He is also a Director of Imbria.

Previously, Houman co-founded the services company Cardiac Report in 2003, as well as Heart Metabolics in 2008. Heart Metabolics successfully repositioned perhexiline, as a treatment for hypertrophic cardiomyopathy and heart failure. Perhexiline is now in advanced clinical trials and has orphan drug designation. He went on to become Vice President and head of the Clinical Science Group at UCB Pharma.

Outside of SV, following completion of his cardiology training, Houman was appointed as an Honorary Consultant Cardiologist in 2011 at the John Radcliffe Hospital in Oxford. He is Visiting Professor and Head of Experimental Therapeutics at the University of Oxford. Additionally, Houman is co-founder and Chairman of Weatherden, a boutique clinical development company.

Undergraduate degree, University of Cambridge; BM BCh, DPhil, University of Oxford.